# Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

> **NCT02097524** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 105 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02097524
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2015-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097524, "Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02097524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*